Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Amphastar Pharmaceuticals Inc v. Aventis Pharma SA et al
Case Number:
5:09-cv-00023
Court:
Nature of Suit:
Judge:
Firms
- Brower Law Group
- Gibson Dunn
- Greenberg Gross
- Herrera Kennedy
- Kendall Brill
- K&L Gates
- Michelman & Robinson
- Nixon Peabody
- Sidley Austin
- Stradling Yocca
Companies
Government Agencies
Sectors & Industries:
-
November 15, 2012
Sanofi Dodges Amphastar's FCA Suit Over Lovenox
A federal judge in California on Wednesday dismissed a whistleblower lawsuit filed by Amphastar Pharmaceuticals Inc. alleging competitor Sanofi-Aventis SA illegally conspired to monopolize the market for its patented anti-coagulant drug Lovenox, resulting in state and federal governments paying grossly inflated prices for the medication.
-
October 01, 2012
Sanofi Gets Reprieve In Amphastar's Lovenox FCA Suit
A California federal judge on Friday dismissed a False Claims Act suit accusing Sanofi-Aventis SA of making false patent claims for anti-clotting drug Lovenox to unfairly keep generic competition off the market, but the ruling gave plaintiff Amphastar Pharmaceuticals Inc. leave to amend its complaint.
- ← Previous
- 1
- 2
- Next →